創維數字(000810.SZ):將於1月9日-1月12日美國CES展期間展出創維Pancake2、Pancake1兩款MR頭顯以及A1 AR眼鏡產品
格隆匯1月8日丨有投資者於投資者互動平台向創維數字(000810.SZ)提問,“貴公司是否於明日全球首發新技術路徑的MR頭顯設備?”,公司回覆稱,公司將於2024年1月9日-1月12日美國CES展期間展出創維Pancake2、Pancake1兩款MR頭顯以及A1 AR眼鏡產品。其中,Pancake2為首次亮相,產品配備雙4K級Micro-OLED屏幕,分辨率為3552×3840×2。此外,產品具備VST能力,並搭載手勢追蹤等功能。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.